Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on May 10, 2015 11:22am

191 Views

Post# 23712784

RE:RVX-208 is a derivative of the plant polyphenol resveratrol

Hi esopbykelso.

This is a remarkable post from a research paper relating to rvx-208 approved for publication on October 23 or 2013.

I have read this and the paper and it seems to bode well for rvx-208 selective BET inhibition as reviewed and vetted by independent scientists. Hope I understood that properly.

I would urge all and particularly the science posters to review and provide POVs on this publication.

Thanks so much.
Best regards.
Toinv

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?